Tiziana Life Sciences PLC Sponsored ADR ist eine Aktie aus dem Premium-Bereich von aktien.guide. Bitte anmelden, um einen Alarm für Tiziana Life Sciences PLC Sponsored ADR zu aktivieren.
Kostenlos registrieren
Bitte registriere Dich kostenlos, um Tiziana Life Sciences PLC Sponsored ADR zu Deinem Portfolio hinzuzufügen.
Tiziana Life Sciences PLC Sponsored ADR Aktie News
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced positive results from studies of a nasal anti-CD3 monoclonal antibody in traumatic spinal cord injury (SCI). SCI represents a major global health concern with significant effects on mortality and long-term disability, the company said in a statement on Thursday.
NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced results from studies using a nasal anti-CD3 monoclonal antibody in traumatic spinal c...
NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces its intention not to engage in a capital raising activities for the immediate future.
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with its novel therapy nasal foralumab. The company's study detected changes in gene expression starting three months after patients received intranasal foralumab in the ongoing ISPPEA (Expanded Access Program).
NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the discovery of new immune biomarkers in patients with non-active secondary progress...
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its intranasal anti-CD3 monoclonal antibody, foralumab, has demonstrated the ability to mitigate the side effects associated with the discontinuation of GLP-1 agonists, medicines used to manage Type 2 diabetes and obesity. GLP-1 agonists, such as semaglutide marketed under brand names like Ozempic and Wegovy, are integral in treating metabo...
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the publication of a review article in Nature Reviews Neurology that examines the potential of its lead therapeutic candidate intranasal foralumab in treating various neurodegenerative diseases such as Multiple Sclerosis (MS), Alzheimer's disease, ALS, and Parkinson's disease. The article, titled “Immune mechanisms and shared immune targets ...
NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that a review article titled “Immune mechanisms and shared immune targets in neurodeg...
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.